AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Actinium Pharmaceuticals, Inc.

$1.4 +$0.03 (+2.19%)
AMEX · 11 Sep 2026 20:00 UTC
Previous Close
$1.31
Day Range
$1.31$1.42
Year Range
$0.73$1.74
Market Cap
43.92M
AVG Volume
137.83K
Trailing/Forward PE
3.89/-
PEG ratio
-0.01
Dividend Yield
-
Next Earnings Date
2026-11-13
Primary Exchange
New York Stock Exchange ArcaUS
Revenue (USD) · TTM
010M20M30M40M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q235.09M
26 Q190K
25 Q490K
25 Q390K
25 Q20
25 Q10
24 Q40
24 Q381K
24 Q281K
24 Q181K
Net Income (USD) · TTM
-60M-40M-20M020M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q211.31M
26 Q1-23.47M
25 Q4-33.89M
25 Q3-34.6M
25 Q2-41.04M
25 Q1-45.51M
24 Q4-38.24M
24 Q3-40.91M
24 Q2-42.62M
24 Q1-46.45M
Operating Income (USD) · TTM
-60M-40M-20M020M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q29.56M
26 Q1-25.51M
25 Q4-36.25M
25 Q3-37.34M
25 Q2-44.25M
25 Q1-49.16M
24 Q4-42.12M
24 Q3-44.96M
24 Q2-46.71M
24 Q1-49.93M
EBITDA (USD) · TTM
-60M-40M-20M020M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q212.18M
26 Q1-22.64M
25 Q4-33.07M
25 Q3-33.78M
25 Q2-40.22M
25 Q1-44.71M
24 Q4-37.43M
24 Q3-40.11M
24 Q2-41.82M
24 Q1-45.63M
Cash Flows (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-23.25M
26 Q1-22.98M
25 Q4-24.68M
25 Q3-25.04M
25 Q2-30.69M
25 Q1-33.27M
24 Q4-33.08M
24 Q3-34.82M
24 Q2-34M
24 Q1-39.72M
EPS (USD) · TTM
-2-10124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q20.36
26 Q1-0.75
25 Q4-1.08
25 Q3-1.1
25 Q2-1.31
25 Q1-1.47
24 Q4-1.27
24 Q3-1.4
24 Q2-1.52
24 Q1-1.72
Expenses (USD) · TTM
020M40M60MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q226.73M
26 Q126.32M
25 Q437.06M
25 Q337.22M
25 Q243.84M
25 Q148.57M
24 Q441.32M
24 Q344.24M
24 Q246.03M
24 Q149.28M
Shares Outstanding (USD) · TTM
-15M-10M-5M05MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ATNM Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-30K
26 Q1-109K
25 Q4-8.98M
25 Q3-10.18M
25 Q2-11.61M
25 Q1-12.79M
24 Q4-5.29M
24 Q3-5.02M
24 Q2-4.6M
24 Q1-4.23M
Employee Count
02040602016201720182019202020212022202320242025
ATNM Employee Count by quarter
PeriodEmployee Count
202525
202437
202349
202249
202132
202032
201925
201830
201725
201623
PE Ratio
22.533.54med 2.87Aug 26Aug 26Aug 26Aug 26Sep 26Sep 26
ATNM PE Ratio by quarter
PeriodPE Ratio
Sep 263.89
Sep 262.86
Aug 262.8
Aug 263.05
Aug 262.89
Aug 262.21
Free Cash Flow Yield
-120%-100%-80%-60%-40%med -69.91%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ATNM Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-52.88%
Sep 26-71.88%
Aug 26-73.3%
Aug 26-67.31%
Aug 26-71.19%
Aug 26-92.85%
Jul 26-87.91%
Jul 26-85.55%
Jul 26-79.8%
Jul 26-79.11%
Jul 26-75%
Jun 26-74.31%
Jun 26-71.43%
Jun 26-72.84%
Jun 26-68.12%
May 26-58.39%
May 26-62.35%
May 26-58.86%
May 26-56.16%
May 26-70.02%
Apr 26-61.82%
Apr 26-60.87%
Apr 26-73.26%
Apr 26-80.71%
Mar 26-77.94%
Mar 26-72.32%
Mar 26-72.32%
Mar 26-66.89%
Feb 26-68.03%
Feb 26-75.73%
Feb 26-72.32%
Feb 26-69.8%
Jan 26-69.2%
Jan 26-61.75%
Jan 26-60.36%
Jan 26-57.75%
Jan 26-58.59%
Dec 25-52.81%
Dec 25-47.5%
Dec 25-53.16%
Dec 25-56.14%
Nov 25-58.17%
Nov 25-60.36%
Nov 25-63.21%
Nov 25-78.08%
Oct 25-68.8%
Oct 25-58.91%
Oct 25-67.39%
Oct 25-66.03%
Oct 25-62.27%
Sep 25-61.11%
Sep 25-61.88%
Sep 25-60.36%
Sep 25-62.27%
Aug 25-55.27%
Aug 25-56.54%
Aug 25-58.22%
Aug 25-63.89%
Aug 25-66.25%
Jul 25-59.58%
Jul 25-62.37%
Jul 25-70.17%
Jul 25-74.07%
Jun 25-75.11%
Jun 25-71.1%
Jun 25-71.58%
Jun 25-58.28%
May 25-69.26%
May 25-65.03%
May 25-63.87%
May 25-72.06%
May 25-68.42%
Apr 25-80.95%
Apr 25-87.64%
Apr 25-81.58%
Apr 25-82.21%
Mar 25-61.92%
Mar 25-72.3%
Mar 25-91.12%
Mar 25-98.31%
Feb 25-97.45%
Feb 25-95.79%
Feb 25-97.45%
Feb 25-100.06%
Jan 25-96.61%
Jan 25-86.88%
Jan 25-80.05%
Jan 25-87.56%
Jan 25-77.83%
Dec 24-93.39%
Dec 24-86.88%
Dec 24-91.12%
Dec 24-82.41%
Nov 24-77.83%
Nov 24-77.29%
Nov 24-74.71%
Nov 24-58.83%
Nov 24-66.05%
Oct 24-67.23%
Oct 24-62.06%
Price to Sales
01000200030004000med 492.92May 24Aug 24Dec 24Mar 25Feb 26May 26Sep 26
ATNM Price to Sales by quarter
PeriodPrice to Sales
Sep 261.25
Sep 260.92
Aug 260.9
Aug 260.98
Aug 260.93
Aug 260.71
Jul 26290.48
Jul 26298.49
Jul 26319.98
Jul 26322.79
Jul 26340.49
Jun 26343.61
Jun 26357.5
Jun 26350.56
Jun 26374.85
May 26437.33
May 26409.56
May 26433.86
May 26454.68
May 26391.68
Apr 26443.67
Apr 26450.61
Apr 26374.35
Apr 26339.83
Mar 26357.02
Mar 26384.75
Mar 26384.75
Mar 26415.95
Feb 26409.01
Feb 26367.42
Feb 26384.75
Feb 26398.61
Jan 26402.08
Jan 26450.61
Jan 26461.01
Jan 26481.8
Jan 26474.87
Dec 25526.86
Dec 25585.79
Dec 25523.4
Dec 25495.67
Nov 25478.34
Nov 25461.01
Nov 25440.21
Mar 25694.3
Mar 25594.57
Mar 25471.82
Mar 25437.3
Feb 25441.13
Feb 25448.8
Feb 25441.13
Feb 25429.62
Jan 25444.97
Jan 25494.83
Jan 25537.03
Jan 25491
Jan 25552.37
Dec 24460.31
Dec 24494.83
Dec 24471.82
Dec 24521.69
Nov 24552.37
Nov 24556.21
Nov 24575.39
Nov 24713.55
Nov 24635.51
Oct 24624.36
Oct 24676.39
Oct 24668.96
Oct 24665.24
Sep 24668.96
Sep 24668.96
Sep 24691.25
Sep 24661.52
Aug 24739.57
Aug 24747
Aug 24676.39
Aug 24761.87
Aug 242124.16
Jul 242692.2
Jul 242447.77
Jul 242564.82
Jul 242399.57
Jun 242547.61
Jun 242516.63
Jun 242692.2
Jun 242740.4
May 242805.81
May 242926.31
May 243373.86
May 243005.49
May 243084.67
Apr 242365.15
Apr 242336.95
Apr 243070.44
Apr 243254.67
Oct 233146.16
Oct 233326.77
Oct 233454.95
Oct 233536.52
EV/EBITDA
-1-0.500.51med -0.22Aug 26Aug 26Aug 26Aug 26Sep 26Sep 26
ATNM EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 260.72
Sep 26-0.23
Aug 26-0.28
Aug 26-0.05
Aug 26-0.2
Aug 26-0.83
Price/Operating Cashflow
101520253035med 22.38Sep 22Oct 22Nov 22Jan 23Feb 23Mar 23May 23
ATNM Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
May 2324.77
May 2326.14
Apr 2326.14
Apr 2327.62
Apr 2327.06
Apr 2326.67
Mar 2328.07
Mar 2320.48
Mar 2320.35
Mar 2318.66
Mar 2322.21
Feb 2320.31
Feb 2330.17
Feb 2328.51
Feb 2326.77
Jan 2325.35
Jan 2324.12
Jan 2322.26
Jan 2321.66
Dec 2223.35
Dec 2222.02
Dec 2224.32
Dec 2223.62
Dec 2224.71
Nov 2224.12
Nov 2226.16
Nov 2224.46
Nov 2222.5
Oct 2220.08
Oct 2214.88
Oct 2215.25
Oct 2215.89
Sep 2215.23
Sep 2215.07
Sep 2216.47
Sep 2217.5
Sep 2216.43
Aug 2213.77
Aug 2212.14
Aug 2212.2
Price to Book
05101520med 2.34Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
ATNM Price to Book by quarter
PeriodPrice to Book
Sep 261.45
Sep 261.07
Aug 261.05
Aug 261.14
Aug 261.08
Aug 260.83
Jul 2611.35
Jul 2611.66
Jul 2612.5
Jul 2612.61
Jul 2613.3
Jun 2613.42
Jun 2613.96
Jun 2613.69
Jun 2614.64
May 2617.08
May 2616
May 2616.95
May 2617.76
May 264.5
Apr 265.1
Apr 265.18
Apr 264.3
Apr 263.9
Mar 262.33
Mar 262.51
Mar 262.51
Mar 262.72
Feb 262.67
Feb 262.4
Feb 262.51
Feb 262.6
Jan 262.63
Jan 262.94
Jan 263.01
Jan 263.15
Jan 263.1
Dec 253.44
Dec 253.82
Dec 253.42
Dec 253.24
Nov 253.12
Nov 253.01
Nov 252.87
Nov 252.07
Oct 252.35
Oct 252.74
Oct 252.4
Oct 252.44
Oct 252.59
Sep 252.64
Sep 252.61
Sep 252.67
Sep 252.59
Aug 252.92
Aug 252.85
Aug 252.77
Aug 252.53
Aug 251.95
Jul 252.17
Jul 252.08
Jul 251.85
Jul 251.75
Jun 251.72
Jun 251.82
Jun 251.81
Jun 252.22
May 251.87
May 251.99
May 252.03
May 251.8
May 251.48
Apr 251.25
Apr 251.15
Apr 251.24
Apr 251.23
Mar 251.47
Mar 251.26
Mar 251
Mar 250.93
Feb 250.94
Feb 250.95
Feb 250.94
Feb 250.91
Jan 250.94
Jan 251.05
Jan 251.14
Jan 251.04
Jan 251.17
Dec 240.98
Dec 241.05
Dec 241
Dec 241.11
Nov 241.17
Nov 241.18
Nov 241.22
Nov 241.32
Nov 241.17
Oct 241.15
Oct 241.25
Actinium Pharmaceuticals, Inc.
ATNM
Stockpicker

Video analysis: ATNM

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ATNM

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

prnewswire.com · 4 Sep 2026

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C.

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

prnewswire.com · 14 Aug 2026

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of its NYSE American listing.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast

defenseworld.net · 30 Jul 2026

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Actinium Pharmaceuticals and

Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review

defenseworld.net · 26 Jul 2026

Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Palatin Technologies (OTCMKTS:PTNT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Valuation and Earnings This table compares Actinium

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.